Vdac modulators for blistering skin conditions
AssigneesThe Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center, The National Institute for Biotechnology In the Negev Ltd.
InventorsEli SPRECHER, Ofer SARIG, Sari ASSAF, Varda SHOSHAN-BARMATZ
Life of this patent
Estimating the term…
Abstract
The invention provides compositions and methods for treating a group of rare autoimmune blistering skin conditions resulting from defective epidermal and mucosal cell adhesion such as pemphigus and pemphigoid.
Claims21
-41. (canceled)
A method for slowing the progression or treating a skin disorder associated with a defect of epidermal and/or subepidermal cells adhesion in a human subject, the method comprises topical or oral administering to said subject a therapeutically effective amount at least one modulator of at least one voltage-dependent anion channel isoform VDAC1, 2 or 3.
An oral or a topical composition for slowing the progression or treating a skin disorder associated with a defect of epidermal and/or subepidermal cells adhesion, the composition comprising an effective amount of at least one modulator of at least one voltage-dependent anion channel isoform VDAC1, 2 or 3.
Dependencies are inferred from the claim text.